This federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $2,531,888 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to study "CORRECTING CYTOSKELETAL ABNORMALITIES AND PODOCYTE VULNERABILITY IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS." The 4-year award, starting on May 1, 2024, supports Bidmc's research aimed at improving treatments for this kidney disorder. As a leading academic medical center, Bidmc has an extensive portfolio of federal grant and contract work supporting medical research and clinical care initiatives. This award exemplifies the Defense Health Agency's efforts to advance innovative biomedical solutions that address health challenges relevant to military personnel and the broader public.
Generated 1/28/25, 7:39 AM